MERCK & CO., INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 131.2 USD | +0.40% |
|
+4.46% | +20.52% |
| 04:48pm | Guggenheim Adjusts Price Target on Merck to $146 From $144 | MT |
| 04:37pm | Wells Fargo Adjusts Price Target on Merck & Company to $140 From $135 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
2024-05-28
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
130.7
USD
Average target price
139.6
USD
Spread / Average Target
+6.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.38% | 331B | |
| +25.64% | 653B | |
| +26.37% | 556B | |
| -6.52% | 354B | |
| +4.52% | 296B | |
| +12.87% | 233B | |
| +5.48% | 201B | |
| -9.49% | 193B | |
| -6.05% | 144B | |
| -11.91% | 143B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Earnings Flash (MRK) MERCK & CO. Posts Q4 EPS $1.62
